Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 5, 2024. The report addresses the company's compliance status with Nasdaq listing requirements regarding its common stock (Trading Symbol: SLRX).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on regulatory compliance regarding stock price.
Material Changes
- Nasdaq Compliance Status: The company previously failed to meet Nasdaq Listing Rule 5550(a)(2) (Bid Price Rule) as its stock closed below $1.00 for 30 consecutive business days.
- Extension Granted: Nasdaq granted an additional 180-day grace period extending until September 3, 2024, to regain compliance.
- Compliance Requirement: To maintain listing, the minimum bid price must reach at least $1.00 for 10 consecutive business days on or before September 3, 2024.
Outlook, Risks, and Contingencies
- Delisting Risk: Failure to regain compliance by the September 3, 2024 deadline will result in a Nasdaq determination to delist the common stock.
- Appeal Process: If delisted, the company may appeal to a Nasdaq Listing Qualifications Panel, though there is no assurance of success.
- Reverse Stock Split: As a condition of the approval, the company has notified Nasdaq of its intent to implement a reverse stock split if necessary to meet the bid price requirement.
Investor Verification Checklist
- Verify the current trading price of SLRX relative to the $1.00 threshold.
- Monitor for any future announcements regarding the implementation of a reverse stock split.
- Track the company's progress toward maintaining a $1.00 bid price for 10 consecutive days before September 3, 2024.
- Confirm the company's cash position and runway, as this filing does not disclose financial health metrics.